TBC1D16 inhibitors are a class of chemical compounds designed to target and inhibit the activity of the TBC1D16 protein, a member of the TBC1 domain family that acts as a GTPase-activating protein (GAP). TBC1D16 regulates the activity of Rab GTPases, a group of small GTP-binding proteins that play a crucial role in intracellular vesicular trafficking. These Rab proteins act as molecular switches, cycling between active GTP-bound states and inactive GDP-bound states, which controls the transport of vesicles between different cellular compartments. TBC1D16 accelerates the hydrolysis of GTP to GDP, thereby turning off Rab GTPase activity and influencing various cellular processes such as endocytosis, exocytosis, and the recycling of membrane-bound proteins. By inhibiting TBC1D16, these compounds interfere with the regulation of Rab GTPase activity, which can impact the proper sorting and trafficking of intracellular cargo.
The study of TBC1D16 inhibitors provides researchers with insights into the specific roles of this GAP in regulating intracellular transport pathways. By blocking TBC1D16 activity, scientists can explore how disruptions in Rab GTPase regulation affect vesicle movement and membrane dynamics, particularly in pathways that involve the recycling of receptors and other membrane proteins. These inhibitors serve as valuable tools for understanding the intricate networks of protein interactions that control vesicular transport and how alterations in these processes can influence cellular homeostasis. Additionally, TBC1D16 inhibitors help illuminate the broader role of the TBC1 domain family in modulating Rab GTPase activity and how this modulation contributes to the spatial and temporal regulation of intracellular trafficking. Through these studies, researchers can gain a deeper understanding of how vesicular transport is coordinated within cells, advancing knowledge of cellular organization and function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor that inhibits downstream signaling pathways regulated by TBC1D16. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that blocks the PI3K/Akt pathway which TBC1D16 can regulate. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that interrupts signaling pathways that TBC1D16 can influence. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that disrupts the MAPK/ERK pathway which TBC1D16 can modulate. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that affects stress response pathways associated with TBC1D16. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
A JNK inhibitor that alters signaling pathways involved in processes regulated by TBC1D16. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Another MEK inhibitor that prevents the activation of the MAPK/ERK pathway regulated by TBC1D16. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A Src family kinase inhibitor that disrupts multiple signaling pathways including those involving TBC1D16. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A Src kinase inhibitor that alters signaling cascades that TBC1D16 can affect. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
A Rac1 inhibitor that interferes with the actin cytoskeleton regulation, a process TBC1D16 is associated with. |